MedTrace Logo

Phase 1 Study of HRS-9231 Safety and Pharmacokinetics in Healthy Caucasians

NCT06519981 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-12-06

No results posted yet for this study

Summary

This is a phase 1, randomized, double-blind, placebo-controlled study. The objective of this study is to evaluate the safety, tolerability, and PK profile of HRS-9231 injection following a single dose in healthy Caucasian participants.

Conditions

  • MRI

Interventions

DRUG

HRS-9231or matching placebo

HRS-9231 injection or matching placebo will be administered through IV injection.

Sponsors & Collaborators

  • Atridia Pty Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-08-21
Primary Completion
2024-09-29
Completion
2024-11-27

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06519981 on ClinicalTrials.gov